Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
27 Jun 2023
Historique:
accepted: 02 01 2023
received: 07 07 2022
medline: 19 6 2023
pubmed: 11 2 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

Engraftment and differentiation of donor hematopoietic stem cells is decisive for the clinical success of allogeneic stem cell transplantation (alloSCT) and depends on the recipient's bone marrow (BM) niche. A damaged niche contributes to poor graft function after alloSCT; however, the underlying mechanisms and the role of BM multipotent mesenchymal stromal cells (MSC) are ill-defined. Upon multivariate analysis in 732 individuals, we observed a reduced presence of proliferation-capable MSC in BM aspirates from patients (N = 196) who had undergone alloSCT. This was confirmed by paired analysis in 30 patients showing a higher frequency of samples with a lack of MSC presence post-alloSCT compared with pre-alloSCT. This reduced MSC presence was associated with reduced survival of patients after alloSCT and specifically with impaired graft function. Post-alloSCT MSC showed diminished in vitro proliferation along with a transcriptional antiproliferative signature, upregulation of epithelial-mesenchymal transition and extracellular matrix pathways, and altered impact on cytokine release upon contact with hematopoietic cells. To avoid in vitro culture bias, we isolated the CD146+/CD45-/HLA-DR- BM cell fraction, which comprised the entire MSC population. The post-alloSCT isolated native CD146+MSC showed a similar reduction in proliferation capacity and shared the same antiproliferative transcriptomic signature as for post-alloSCT colony-forming unit fibroblast-derived MSC. Taken together, our data show that alloSCT confers damage to the proliferative capacity of native MSC, which is associated with reduced patient survival after alloSCT and impaired engraftment of allogeneic hematopoiesis. These data represent the basis to elucidate mechanisms of BM niche reconstitution after alloSCT and its therapeutic manipulation.

Identifiants

pubmed: 36763527
pii: 494457
doi: 10.1182/bloodadvances.2022008510
pmc: PMC10279553
doi:

Substances chimiques

CD146 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2811-2824

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Nature. 1987 Jul 30-Aug 5;328(6129):429-32
pubmed: 2886914
Cytotherapy. 2020 Jan;22(1):21-26
pubmed: 31883948
Cell Rep. 2013 May 30;3(5):1714-24
pubmed: 23623496
Cytotherapy. 2015 Feb;17(2):186-98
pubmed: 25593077
Blood Adv. 2022 Jan 11;6(1):108-120
pubmed: 34625796
Blood. 2007 Oct 1;110(7):2764-7
pubmed: 17638847
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Cell Stem Cell. 2017 Aug 3;21(2):166-177
pubmed: 28777943
Dev Cell. 2021 Jul 12;56(13):1848-1860
pubmed: 34146467
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8932-7
pubmed: 12084934
Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8
pubmed: 33301706
Stem Cell Res Ther. 2021 Dec 7;12(1):601
pubmed: 34876206
Stem Cells. 2018 Jan;36(1):123-129
pubmed: 29067757
Cell Stem Cell. 2014 Aug 7;15(2):154-68
pubmed: 24953181
J Clin Invest. 2019 Feb 25;129(4):1566-1580
pubmed: 30830876
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Bone Marrow Transplant. 2004 Apr;33(7):729-34
pubmed: 14755315
Blood. 2011 May 12;117(19):5067-77
pubmed: 21415267
Cell Stem Cell. 2008 Sep 11;3(3):301-13
pubmed: 18786417
J Transl Med. 2019 Jan 11;17(1):23
pubmed: 30635013
Cell. 2007 Oct 19;131(2):324-36
pubmed: 17956733
Stem Cell Res Ther. 2018 Oct 25;9(1):271
pubmed: 30359303
Cell Stem Cell. 2017 Aug 3;21(2):241-255.e6
pubmed: 28777945
Stem Cells. 2006 Dec;24(12):2753-65
pubmed: 16931776
Haematologica. 2018 Sep;103(9):1462-1471
pubmed: 29773599
Cell Transplant. 2007;16(6):579-85
pubmed: 17912949
Exp Hematol. 1999 Nov;27(11):1675-81
pubmed: 10560915
Cell Stem Cell. 2022 Nov 3;29(11):1515-1530
pubmed: 36332569
BMC Genomics. 2014 Oct 19;15:910
pubmed: 25326687
Bone Marrow Transplant. 2018 Nov;53(11):1379-1389
pubmed: 29670211
Blood. 2015 Nov 26;126(22):2443-51
pubmed: 26468230

Auteurs

Christiane Katzerke (C)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Judith Schaffrath (J)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Jana Lützkendorf (J)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Maike Janssen (M)

Klinik für Innere Medizin V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit, European Molecular Biology Laboratory-Universitätsklinikum Heidelberg, Heidelberg, Germany.

Anne-Kathrin Merbach (AK)

Klinik für Innere Medizin V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit, European Molecular Biology Laboratory-Universitätsklinikum Heidelberg, Heidelberg, Germany.

Katrin Nerger (K)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Mascha Binder (M)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Cornelia Baum (C)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Kirstin Lauer (K)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Christian Rohde (C)

Klinik für Innere Medizin V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit, European Molecular Biology Laboratory-Universitätsklinikum Heidelberg, Heidelberg, Germany.

Edith Willscher (E)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Carsten Müller-Tidow (C)

Klinik für Innere Medizin V, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit, European Molecular Biology Laboratory-Universitätsklinikum Heidelberg, Heidelberg, Germany.

Lutz P Müller (LP)

Universitätsklinik und Poliklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle (Saale), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH